Pipeline
Oncology
iconArrow
Candidate
Gene Targets
Indications
Delivery Platform
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Commercial Rights
STP705*
More+
TGF-β1/COX-2
Gene Targets:
TGF-β1/COX-2
Indications:

isSCC

Delivery Platform:
PNP-IT
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

isSCC

US

isSCC

China (MRCT)52

Commercial Rights:
Global
Gene Targets:
TGF-β1/COX-2
Indications:

BCC

Delivery Platform:
PNP-IT
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

BCC

US

Commercial Rights:
Global
Gene Targets:
TGF-β1/COX-2
Indications:

Liver Cancer1 (Basket) **

Delivery Platform:
PNP-IT
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Liver Cancer1 (Basket) **

US

Liver Cancer1 (Basket) **

China (MRCT)3

Commercial Rights:
Global
Gene Targets:
TGF-β1/COX-2
Indications:

Liver Cancer, combo with anti-PD-(L)1

Delivery Platform:
PNP-IT
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Liver Cancer, combo with anti-PD-(L)1

US

Commercial Rights:
Global
View More+
STP707
More+
TGF-β1/COX-2
Gene Targets:
TGF-β1/COX-2
Indications:

Liver Cancer1 (Basket)**

Delivery Platform:
PNP-IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Liver Cancer1 (Basket)**

US

Liver Cancer1 (Basket)**

China (MRCT)4

Commercial Rights:
Global
Gene Targets:
TGF-β1/COX-2
Indications:

cSCC

Delivery Platform:
PNP-IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

cSCC

US

Commercial Rights:
Global
Gene Targets:
TGF-β1/COX-2
Indications:

NSCLC

Delivery Platform:
PNP-IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

NSCLC

US

Commercial Rights:
Global
Gene Targets:
TGF-β1/COX-2
Indications:

Liver Cancer, cSCC, NSCLC, combo with anti-PD-(L)1

Delivery Platform:
PNP-IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Liver Cancer, cSCC, NSCLC, combo with anti-PD-(L)1

US

Commercial Rights:
Global
View More+
STP355
More+
TGF-β1/VEGFR2
Gene Targets:
TGF-β1/VEGFR2
Indications:

Pan Cancer

Delivery Platform:
PNP-IT/IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Pan Cancer

US

Commercial Rights:
Global
View More+
STP369
More+
BCL-xL/MCL-1
Gene Targets:
BCL-xL/MCL-1
Indications:

Head & Neck Cancer/Bladder Cancer

Delivery Platform:
PNP-IT / IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Head & Neck Cancer/Bladder Cancer

US

Commercial Rights:
Global
View More+
STP779
More+
TGF-β1/SULF-2
Gene Targets:
TGF-β1/SULF-2
Indications:
Liver Cancer/ Lung Cancer/ Pancreatic Cancer
Delivery Platform:
PNP-IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Liver Cancer/ Lung Cancer/ Pancreatic Cancer
US
Commercial Rights:
Global
View More+
STP902
More+
RAF-1
Gene Targets:
RAF-1
Indications:

Breast Cancer

Delivery Platform:
PNP-IT / IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Breast Cancer

Commercial Rights:
Global
View More+
Fibrosis
iconArrow
Candidate
Gene Targets
Indications
Delivery Platform
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Commercial Rights
STP705*
More+
TGF-β1/COX-2 
Gene Targets:
TGF-β1/COX-2 
Indications:

Keloid Scarless Healing**

Delivery Platform:
PNP-ID
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Keloid Scarless Healing**

US

Commercial Rights:
Global
Gene Targets:
TGF-β1/COX-2 
Indications:

Hypertrophic Scarring

Delivery Platform:
PNP-ID
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Hypertrophic Scarring

US

Hypertrophic Scarring

China(MRCT)5

Hypertrophic Scarring

China

Commercial Rights:
Global
View More+
STP707
More+
TGF-β1/COX-2 
Gene Targets:
TGF-β1/COX-2 
Indications:

Liver Fibrosis (PSC)

Delivery Platform:
PNP-IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Liver Fibrosis (PSC)

US

Liver Fibrosis (PSC)

China(MRCT)
Commercial Rights:
Global
Gene Targets:
TGF-β1/COX-2 
Indications:
Lung Fibrosis
Delivery Platform:
PNP-IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Lung Fibrosis
US
Commercial Rights:
Global
View More+
Medical Aesthetic
iconArrow
Candidate
Gene Targets
Indications
Delivery Platform
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Commercial Rights
STP705*
More+
TGF-ß1/COX-2
Gene Targets:
TGF-ß1/COX-2
Indications:

Fat Sculpting

Delivery Platform:
PNP-ID
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Fat Sculpting

US

Commercial Rights:
Global
View More+
Antiviral
iconArrow
Candidate
Gene Targets
Indications
Delivery Platform
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Commercial Rights
STP702
More+
M1/PA
Gene Targets:
M1/PA
Indications:

Influenza

Delivery Platform:
Airway / PNP-IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Influenza

US

Commercial Rights:
OL China
View More+
STP908
More+
ORF1Ab/N-protein
Gene Targets:
ORF1Ab/N-protein
Indications:

Covid-19

Delivery Platform:
Airway / PNP-IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Covid-19

US

Commercial Rights:
Global
View More+
RIM730
More+
SARS-CoV2
Gene Targets:
SARS-CoV2
Indications:

Covid-19 Vaccine

Delivery Platform:
LNP​ Intramuscular
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Covid-19 Vaccine

US

Commercial Rights:
Global
View More+
STP909
More+
VP16/18-E7
Gene Targets:
VP16/18-E7
Indications:

HPV/Cervical Cancer

Delivery Platform:
PNP-IV/Topical
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

HPV/Cervical Cancer

Commercial Rights:
Global
View More+
GaINAc-RNAi triggers
iconArrow
Candidate
Gene Targets
Indications
Delivery Platform
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Commercial Rights
STP122G
More+
Factor XI
Gene Targets:
Factor XI
Indications:

Anticoagulant

Delivery Platform:
GalAhead™​ subcutaneous
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Anticoagulant

US

Commercial Rights:
Global
View More+
STP133G
More+
PCSK9/ApoC3
Gene Targets:
PCSK9/ApoC3
Indications:
Cardiometabolic
Delivery Platform:
GalAhead™ subcutaneous
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Cardiometabolic
Commercial Rights:
Global
View More+
STP135G
More+
Non-disclosed
Gene Targets:
Non-disclosed
Indications:

Hypercholesterolemia

Delivery Platform:
PDoV-GalNAc subcutaneous
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Hypercholesterolemia

Commercial Rights:
Global
View More+
STP144G
More+
Complement Factor B
Gene Targets:
Complement Factor B
Indications:

Complement-mediated diseases

Delivery Platform:
GalAhead™​ subcutaneous
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Complement-mediated diseases

Commercial Rights:
Global
View More+
STP155G
More+
HBV sequences
Gene Targets:
HBV sequences
Indications:
HBV
Delivery Platform:
PDoV-GalNAc subcutaneous
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
HBV
Commercial Rights:
Global
View More+

Notes:

* denotes our core product

 

** denotes orphan drug

Abbreviations:

isSCC = cutaneous squamous cell carcinoma in situ;

BCC = basal cell carcinoma;

cSCC = metastatic cutaneous squamous cell carcinoma;

NSCLC = non-small cell lung cancer;

CRC = colorectal carcinoma;

BC = bladder cancer;

PSC = primary sclerosing cholangitis;

PNP = our polypeptide nanoparticle (PNP) RNAi delivery platform;

PNP-IT = PNP platform formulated for intratumoral administration;

PNP-IV = PNP platform formulated for intravenous administration;

PNP-ID= PNP platform formulated for intradermal administration;

GalAhead™= our GalNAc RNAi delivery platform that conjugates GalNAc moieties to RNAi triggers;

PDoV-GalNAc = our GalNAc RNAi delivery platform that conjugates GalNAc moieties to Peptide Docking Vehicle (PDoV) peptide linkers and up to two siRNAs to the peptide;

LNP = lipid nanoparticle (LNP) formulation for delivery of mRNA;

HPV = human papilloma virus;

HBV = hepatitis B virus;

OL China = out-licensed mainland China, Hong Kong, Macau and Taiwan rights under agreement with Walvax but we retain the rights for rest of the world; 

MRCT = multi regional clinical trial in which we will be the sponsor for all clinical trial sites;

ID = Intradermal;

 

  1. Liver cancer (basket) includes cholangiocarcinoma, hepatocellular carcinoma, liver metastases etc.
  2. Siranomics filed an IND in China, which is currently awaiting approval from NMPA, for study sites in China. The study sites will be part of a global multicenter study for our Phase IIb clinical trial for isSCC.
  3. Siranomics expects to file an IND in China as part of the global multicenter clinical trials.
  4. Sirnaomics expects to file an IND solely for HCC in China as part of the global multicenter clinical trials.
  5. Studies in combination with anti-PD-(L)1 inhibitors conducted pursuant to collaborations with Innovent and Shanghai Junshi.
  6. Research and development conducted by our subsidiary RNAimmune.